KTRA vs. MRKR, LPCN, CARA, UNCY, PMN, NLTX, RNXT, BOLT, IPA, and VIRX
Should you be buying Kintara Therapeutics stock or one of its competitors? The main competitors of Kintara Therapeutics include Marker Therapeutics (MRKR), Lipocine (LPCN), Cara Therapeutics (CARA), Unicycive Therapeutics (UNCY), ProMIS Neurosciences (PMN), Neoleukin Therapeutics (NLTX), RenovoRx (RNXT), Bolt Biotherapeutics (BOLT), ImmunoPrecise Antibodies (IPA), and Viracta Therapeutics (VIRX). These companies are all part of the "pharmaceutical preparations" industry.
Marker Therapeutics (NASDAQ:MRKR) and Kintara Therapeutics (NASDAQ:KTRA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, earnings, valuation, profitability, community ranking, media sentiment and dividends.
Marker Therapeutics has a beta of 1.54, indicating that its share price is 54% more volatile than the S&P 500. Comparatively, Kintara Therapeutics has a beta of 0.42, indicating that its share price is 58% less volatile than the S&P 500.
22.4% of Marker Therapeutics shares are held by institutional investors. Comparatively, 0.6% of Kintara Therapeutics shares are held by institutional investors. 17.4% of Marker Therapeutics shares are held by company insiders. Comparatively, 0.2% of Kintara Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
In the previous week, Kintara Therapeutics had 1 more articles in the media than Marker Therapeutics. MarketBeat recorded 3 mentions for Kintara Therapeutics and 2 mentions for Marker Therapeutics. Marker Therapeutics' average media sentiment score of 1.19 beat Kintara Therapeutics' score of 0.93 indicating that Kintara Therapeutics is being referred to more favorably in the news media.
Kintara Therapeutics has a net margin of 0.00% compared to Kintara Therapeutics' net margin of -142.62%. Marker Therapeutics' return on equity of 0.00% beat Kintara Therapeutics' return on equity.
Marker Therapeutics has higher revenue and earnings than Kintara Therapeutics.
Marker Therapeutics received 55 more outperform votes than Kintara Therapeutics when rated by MarketBeat users. However, 88.89% of users gave Kintara Therapeutics an outperform vote while only 63.39% of users gave Marker Therapeutics an outperform vote.
Marker Therapeutics currently has a consensus price target of $11.00, indicating a potential upside of 184.24%. Given Kintara Therapeutics' higher probable upside, analysts plainly believe Marker Therapeutics is more favorable than Kintara Therapeutics.
Summary
Marker Therapeutics beats Kintara Therapeutics on 8 of the 13 factors compared between the two stocks.
Get Kintara Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for KTRA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KTRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Kintara Therapeutics Competitors List
Related Companies and Tools
